The effects of glucose-insulin-potassium (GIK) on cardiac metabolism have been studied previously in non-diabetic patients after cardiac surgery. Although patients with diabetes mellitus can be expected to benefit most from such treatment, the impact of GIK in diabetic patients undergoing cardiac surgery remains unexplored. Therefore the present study investigates the effects of high-dose GIK on myocardial substrate utilization after coronary surgery in patients with Type II diabetes. A total of 20 patients with Type II diabetes undergoing elective coronary surgery were randomly allocated to either post-operative high-dose GIK or standard post-operative care, including insulin infusion if necessary to keep blood glucose below 10 mmol/l. Myocardial substrate utilization was studied using the coronary sinus catheter technique. Haemodynamic state was assessed with the aid of Swan-Ganz catheters. High-dose GIK caused a shift towards carbohydrate utilization, with significant lactate uptake throughout the study period and significant uptake of glucose after 4 h. Arterial levels of non-esterified fatty acids and β-hydroxybutyric acid decreased, and after 1 h no significant uptake of these substrates was found. Increases in the cardiac index and stroke volume index were found in patients treated with high-dose GIK. A decrease in systemic vascular resistance was found both in the control group and in the high-dose GIK group. We conclude that high-dose GIK can be used in diabetic patients after cardiac surgery to promote carbohydrate uptake at the expense of non-esterified fatty acids and β-hydroxybutyric acid. This could have implications for treatment of the diabetic heart in association with surgery and ischaemia.
INTRODUCTION
Glucose-insulin-potassium (GIK) has been re-appraised in recent years for the treatment of the heart in association with myocardial infarction and cardiac surgery [1] [2] [3] [4] [5] [6] [7] . The optimum doses of insulin in treatment of myocardial infarction and of cardiac surgery appear to differ markedly. Due to neuroendocrine stress, high doses of insulin are required to achieve maximal metabolic effects after cardiac surgery in non-diabetic patients [8] [9] [10] . Although patients with diabetes mellitus can be expected to benefit most from such treatment, the impact of GIK on cardiac metabolism in diabetic subjects remains unexplored. Therefore the effects of high-dose GIK on myocardial substrate utilization after elective coronary artery bypass graft surgery in patients with Type II diabetes have been investigated.
METHODS

Patients
A total of 20 patients with Type II diabetes undergoing elective coronary surgery for stable angina pectoris were studied. Exclusion criteria were a left ventricular ejection fraction of 0.40, age 80 years, serious late complications of diabetes, liver disease, poorly controlled diabetes or metabolic disturbance other than diabetes. Demographic data are given in Table 1 .
Clinical management
All patients were operated on before 12.00 hours. After an overnight fast, β-blockers and calcium antagonists were administered orally, but ACE (angiotensin-converting enzyme) inhibitors, oral anti-diabetic treatment and insulin were withheld. The patients were premedicated intramuscularly with 8-10 mg of oxicodone and 0.4-0.5 mg of scopolamine. Anaesthesia was induced with thiopentone at a dose of 2-3 mg\kg body weight (BW) and fentanyl at a dose of 30 µg\kg BW. Pancuronium bromide was used for neuromuscular blockade. Anaesthesia was maintained with fentanyl and isoflurane. After sternotomy, 3 mg of heparin\kg BW was given.
Cardiopulmonary bypass was conducted with a membrane oxygenator and a roller pump generating pulsatile flow. The extracorporeal circuit was primed with crystalloid fluid containing no glucose or lactate (Ringer's acetate ; Braun2) and mannitol. Moderate haemodilution (haematocrit 20-25 %) and moderate hypothermia (32- 
Study protocol
The study was performed in accordance with the Helsinki Declaration of Human Rights, and approved by the ethics committee for medical research at Linko$ ping University. Informed consent was obtained from each patient.
The patients were randomly allocated to groups receiving either post-operative high-dose GIK treatment (n l 10) or standard post-operative glucose control (n l 10). The study was not blinded because of the insulin doses used. Originally three arms of the study were considered, with one arm investigating the effect of a GIK regime employing an insulin dose of 0.08 i.u.:h −" :kg −" BW [11] . However, this arm was abandoned after the first patient, because of unacceptable blood glucose control.
The high-dose GIK treatment has been described previously [7] . Briefly fast-acting insulin (Actrapid Novo2) was infused at a rate of 1 i.u.:h −" :kg −" BW for 6 h. A bolus of 25 i.u. was also injected after 5 min. A 30% (w\v) glucose solution supplemented with 10 mmol\l magnesium and 40 mmol\l phosphate was also infused, with the aim of keeping blood glucose between 7 and 10 mmol\l. The average infusion rate was 83 ml\h during the study period. After stopping insulin infusion, the glucose infusion was decreased gradually. Potassium was infused separately.
During the study period, three of the control patients required insulin infusion ranging from 1 to 10 i.u.\h to keep blood glucose levels at 10 mmol\l.
Post-operatively, a coronary sinus catheter (Wilton Webster Labs Inc., Altadena, CA, U.S.A.) was inserted through the right internal jugular vein. The final midcoronary sinus position was confirmed by fluoroscopy and measurement of oxygen saturation. Coronary sinus blood flow (CF 300A Flowmeter ; Webster Labs Inc.) was measured using the retrograde thermodilution technique. The mean of three measurements was used.
The study was started on average 3 h after release of the aortic cross-clamp. Blood sampling from the coronary sinus and radial artery was done in the basal state (before starting GIK) and after 30 min and 1, 2 and 4 h. Haemodynamic state and coronary sinus blood flow were measured at the same time points. Samples for glucose, lactate, glycerol, β-hydroxybutyric acid, glutamate and alanine were analysed in whole blood. Samples for non-esterified fatty acids (NEFA) were analysed in plasma. Details of biochemical analyses have been presented previously [12] .
Myocardial fluxes of substrates were calculated as the product of arterial-coronary-sinus blood or plasma concentration differences and coronary sinus blood or plasma flow, as appropriate [12] . A release of substrates was defined as a myocardial flux value significantly less than zero (P 0.05), whereas uptake of substrates was defined as a myocardial flux significantly greater than zero (P 0.05).
The oxygen consumption of the heart was estimated as the product of the arterial-coronary-sinus blood oxygen content difference and coronary sinus blood flow. Oxy- 
Statistical methods
Statistical analyses were performed with a computerized statistical package (Statistica 5.1 ; StatSoft, Inc., Tulsa, OK, U.S.A.). ANOVA for repeated measures employing the Tukey honest significant difference test was used to analyse inter-group differences (between the GIK and control groups) after the basal state and to analyse changes occurring over time. The Mann-Whitney U-test adjusted for repeated measures with the Bonferroni correction was used to determine statistical differences from zero. Statistical significance was defined as P 0.05. Data are presented as meanspS.E.M.
RESULTS
Clinical outcome
Pre-operative and intra-operative data are presented in Table 1 . There was no mortality. The median stay in the intensive care unit was 1 day for both groups.
Haemodynamic results
Haemodynamic state was stable in both groups during the study period (Table 2 ). In the high-dose GIK group an increase in cardiac index occurred, from 2.1p0.1 litres:min −" :m −# in the basal state to 2.9p0.2 litres:min −" :m −# after 4 h (P 0.05). The stroke volume index increased in the high-dose GIK group, and a reduction in systemic vascular resistance during the study period was observed in both groups. No significant change in left ventricular stroke work index occurred in either group. Inter-group differences (effect of GIK) reached statistical significance only for the cardiac index, but a borderline P value was found for the stroke volume index.
Metabolic findings
Arterial levels of NEFA, β-hydroxybutyric acid and glycerol were significantly lower in the group receiving high-dose GIK treatment than in the control group (Table 3 ). In the control group, the heart extracted NEFA and β-hydroxybutyric acid, but no uptake of carbohydrate substrates was observed (Table 4 ). In the highdose GIK group, uptake of lactate occurred throughout the study period, and at 4 h significant uptake of glucose was also observed (Table 4) . No uptake of NEFA was found during high-dose GIK treatment, and uptake of β-hydroxybutyric acid was observed only during the first 1 h of the study period. Inter-group differences caused by GIK reached statistical significance only for the higher uptake of lactate and the lower uptake of β-hydroxybutyric acid (Table 4) . The difference in lactate Values are meanspS.E.M. HR, heart rate ; CI, cardiac index ; BSA, body surface area ; MAP, mean arterial pressure ; CVP, central venous pressure ; PCWP, pulmonary capillary wedge pressure ; SVRI, systemic vascular resistance index ; LVSWI, left ventricular stroke work index ; SI, stroke index ; S VO 2 , mixed venous oxygen saturation. Statistically significant inter-group differences due to GIK (ANOVA repeated-measures design) are indicated in the right-hand column ; ns, not significant. Post hoc differences are indicated as follows : **P 0.01, ***P 0.001 denote significant differences compared with the basal state (0 h) ; †P 0.05, † †P 0.01, † † †P 0.001 denote significant inter-group differences. Values are meanspS.E.M. Statistically significant inter-group differences due to GIK (ANOVA repeated-measures design) are indicated in the right-hand column ; ns, not significant. Post hoc differences are indicated as follows : **P 0.01, ***P 0.001 denote significant differences compared with the basal state (0 h) ; † †P 0.01, † † †P 0.001 denote significant inter-group differences. 84p28 12088p2559*** † † † 10301p782*** † † † 11125p1464*** † † † 14007p1509*** † † † 0.0001 uptake was explained by a markedly higher rate of extraction during high-dose GIK treatment (P l 0.008).
Variable
Group Basal 30 min 1 h 2 h 4 h P (ANOVA) HR (beats/min) Control 88p5 8 7 p5 8 9 p5 8 9 p4 8 4 p4 GIK 77p4 8 3 p5 8 3 p5 8 3 p5 8 2 p4 n s CI (litres:min − 1 :m −8 1 p4 7 5 p4 7 3 p3 7 2 p3 GIK 88p5 8 0 p4 7 4 p4** 71p3*** 68p3*** ns CVP (mmHg) Control 6p1 6 p1 8 p1 7 p1 8 p1 GIK 6p1 6 p1 7 p1 7 p1 7 p1 n s PCWP (mmHg) Control 10p2 1 0 p2 9 p1 9 p1 9 p1 GIK 10p1 1 0 p1 1 1 p2 1 1 p1 1 1 p1 n
Metabolite
In the high-dose GIK group, the average fractional extraction of lactate increased from 15.9 % in the basal state to 33.8 % at 1 h (P 0.05), and thereafter ranged between 25 % and 32 %. In the control group, the average fractional extraction rate of lactate ranged from a peak of 4.9 % in the basal state to 0.6 % after 4 h. Myocardial 
uptake of glutamate was observed in both groups, but significant release of alanine was only recorded once in the control group. Plasma insulin levels in the high-dose GIK and control groups are given in Table 3 . The average glucose infusion rate in the high-dose GIK group ranged between 4.7p0.2 and 5.1p0.6 mg:min −" :kg −" BW.
DISCUSSION
To our knowledge, this is the first study to investigate the effects of GIK on cardiac metabolism in patients with diabetes. The main finding was that high-dose GIK promoted the myocardial uptake of carbohydrate substrates at the expense of NEFA and β-hydroxybutyric acid early after coronary surgery in patients with Type II diabetes.
Myocardial substrate utilization after cardiac surgery has been studied previously in non-diabetic patients [10, 12, 13] . The metabolic state in these patients was characterized by elevated blood glucose and plasma NEFA, reliance on NEFA for myocardial energy uptake and restricted uptake of carbohydrates. It was also demonstrated that GIK could enhance the myocardial uptake of carbohydrate substrates ; however, due to neuroendocrine stress, insulin doses of up to 1 i.u.:h −" :kg −" BW were required to achieve maximal metabolic effects [8] [9] [10] 13] . This dosage was used in the present study, leading to an approximate 150-fold increase in plasma insulin. Insulin levels of this magnitude are known to be associated with vasodilatation [14] . Our haemodynamic results are in keeping with this, and consequently an increased cardiac index was found in the high-dose GIK group.
In the basal state, satisfactory haemodynamic and metabolic recovery had occurred in both groups. The control patients were treated with insulin, if necessary, to keep blood glucose below 10 mmol\l. In spite of this, no uptake of carbohydrate substrates was observed, and NEFA and β-hydroxybutyric acid were the major substrates taken up by the heart. In contrast, high-dose GIK enhanced the myocardial uptake of carbohydrate substrates, in particular lactate, at the expense of NEFA and β-hydroxybutyric acid. The effect of high-dose GIK on myocardial glucose uptake was not as evident as that on myocardial lactate uptake. Insufficient statistical power due to study size and the relationship between analytical precision and fractional extraction rate could partly explain this discrepancy. Also, the possibilities of an attenuated effect of GIK on myocardial glucose uptake in diabetic patients, or a predominant direct or indirect activation of pyruvate dehydrogenase underlying the action of insulin (discussed below), under these circumstances have to be considered. However, despite conservative statistical assessment, significant uptake of glucose was observed at the end of the study period in the high-dose GIK group, and the uptake of glucose and lactate would have sufficed to explain the entire oxygen consumption, assuming that all substrates taken up by the heart were metabolized. These metabolic findings could have clinical implications, as energy derived from carbohydrates has been claimed to be important for the preservation of mechanical function, structure and ionic balance in association with myocardial ischaemia [8, 15] .
Furthermore, during high-dose GIK treatment, plasma levels of NEFA decreased and no myocardial uptake of NEFA was observed. Although NEFA normally constitute the major source of energy for the heart, a state with elevated NEFA levels and myocardial substrate uptake restricted to predominantly NEFA represents an unfavourable metabolic situation for the ischaemic and post-ischaemic heart, because of increased oxygen expenditure and the accumulation of toxic metabolites [8, 15] . Thus the present study shows that myocardial substrate utilization can be modified in the desired direction even in diabetic patients after cardiac surgery. Also, the results of the present study concerning systemic glucose uptake could have implications for critically ill diabetic patients in settings other than cardiac surgery. By use of high-dose GIK, substantial amounts of energy in the form of glucose could be provided coincident with the maintenance of acceptable blood glucose control. The need for large doses of insulin to achieve this effect was illustrated by the fact that one arm of our study originally designed to investigate the impact of a GIK regime employing an insulin dose of 0.08 i.u.:h −" :kg −" BW [11] was abandoned because of unacceptable blood glucose control.
The methods employed here do not elucidate the precise mechanisms behind the action of high-dose GIK on myocardial substrate uptake. Normally, myocardial uptake of carbohydrate substrates is not insulindependent. In our study high-dose GIK caused marked decreases in arterial levels of NEFA and β-hydroxybutyric acid, which may have indirectly enhanced the uptake of carbohydrates and the activity of pyruvate dehydrogenase [8, 15] . Certainly, the observed impact on myocardial lactate uptake in the absence of a concomitant increase in alanine release is compatible with enhanced pyruvate dehydrogenase activity. Furthermore, insulin can enhance the uptake of carbohydrates directly by stimulating glucose transporters, and possibly by intracellular stimulation of pyruvate dehydrogenase [15, 16] .
Despite encouraging early results with GIK for treatment of acute myocardial infarction in the 1960s and 1970s, it was abandoned due to inconclusive trials. In retrospect, this was done without sufficient statistical power [3] . A meta-analysis including all properly randomized placebo-controlled trials on GIK demonstrated a significant decrease in mortality in acute myocardial infarction [3] , and this was later supported by the ECLA study [2] . With regard to diabetic subjects, two clinical studies have demonstrated encouraging results with GIK for the treatment of myocardial infarction and in association with cardiac surgery [5, 6] . These studies employed substantially lower doses of insulin than in the present study, and the metabolic impact was not investigated. Although it is appreciated that effects other than purely metabolic ones may play a role, it is conceivable that insulin doses sufficient to achieve maximal metabolic effects could enhance the efficacy of this treatment. Further studies are warranted in order to clarify these issues, and to investigate potential clinical benefits or hazards associated with high-dose GIK in clinical practice.
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